Why Standard Oral Glutathione Fails This section explains the pharmacokinetic barrier that makes injectable, IV, and buccal routes necessary for meaningful glutathione repletion
NHS guidance for GLP-1 injections advises inserting the needle straight (at 90) into the fatty layer of the abdomen, thigh, or upper arm never into muscle
It specifically targets GH release
The most common gastrointestinal side effects include: Nausea : Reported in 15-44% of patients (higher rates at Wegovy 2.4 mg), typically most pronounced during dose escalation Diarrhea : Affects approximately 8-30% of users, ranging from mild to moderate severity Vomiting : Occurs in 5-24% of patients (higher rates at Wegovy 2.4 mg), often associated with rapid dose increases Abdominal pain : Experienced by 5-20% of patients, usually described as cramping or discomfort Constipation : Paradoxically affects 3-24% despite the medication's effects on motility Dyspepsia and gastroesophageal reflux : Related to delayed gastric emptying These effects result from semaglutide's pharmacologic action on GLP-1 receptors throughout the gastrointestinal tract
These medications represent one component of cardiovascular risk management, not a standalone solution
